For the latest Coronavirus (COVID-19) updates and frequently asked questions. Please click here

Sciensus Rare: A key partner at World Orphan Drug Congress 2021

Sciensus Rare is delighted to be supporting the upcoming World Orphan Drug Congress (WODC) from 15-18 November in Barcelona, as the event’s networking and partnering sponsor.

The largest and most established orphan drugs and rare diseases meeting of its kind, the WODC is an award-winning event which brings together leading experts and decision-makers under one roof.

Supporting rare disease patients since 1992, Sciensus Rare has also been delivering orphan drugs throughout Europe for over a decade. Today, its portfolio spans 50 different products delivered to over 4,000 customer points across Europe. In the past year alone, it has established partnerships with 40 pharmaceutical companies and supplied 250,000 units of orphan medications for rare and ultra-rare diseases.

An orphan drug is one that is developed to treat an incredibly rare medical condition, meaning it would not be profitable to produce without government assistance such as tax incentives, exclusivity agreements or research subsidies.

As a passionate advocate for making sure every family has access to rare disease medicines and the care they need, Sciensus Rare offers pharmaceutical firms and global biotech companies a tailored, fully managed clinical and commercial service to support the launch and delivery of orphan drugs to patients in Europe and beyond. Thanks to a wealth of clinical expertise, Sciensus Rare can help to improve patient adherence and persistence and real time patient data collection, while ensuring patient safety and delivering a complete solution across the drug lifecycle – from clinical trials in the home through to ongoing patient and family support.

Gareth Williams, President of Sciensus Rare, said:

“We’re thrilled to be part of this year’s WODC and have the opportunity to share Sciensus Rare’s unique offer with so many people in the orphan drugs and rare diseases sector. We are wholeheartedly committed to placing the patient at the heart of what we do. This, combined with our extensive experience and capabilities in all aspects of commercialising products in all European markets, means we can consistently provide launch excellence for our customers and deliver rare and ultra-rare disease medication across Europe when needed.

“We proudly offer our clients a fully tailored and complete solution, allowing them to focus on sales and marketing while we handle the challenging country-to-country regulatory and distribution requirements. Our proven network covers 28 countries and includes established trading relationships with over 4,000 hospitals, retail pharmacy and wholesalers.”

The Sciensus Rare team will be available to meet delegates on stand 35 throughout the congress. For further information, or to book a meeting with one of the team, please contact info-rare@sciensus.com

-ENDS-

About Sciensus Rare

A tailored rare disease medicine service
We believe in making sure every family has access to rare disease medicines and the care they need. No matter where a patient lives or the regulatory governance of that country, we can safely launch and efficiently deliver vital medication and clinical services for families that need it most.

As a partner, we offer a tailored, fully managed service designed to meet the specific challenges of launching and delivering orphan drugs for rare diseases to patients in Europe and beyond. We provide the clinical expertise to improve patient adherence and persistence while ensuring patient safety at all times and deliver a complete solution across the drug lifecycle.

We’re part of Sciensus, a specialist provider of pharmaceutical services, logistics and clinical healthcare in the home. The original company was established in 1992. A year later we began supporting patients and healthcare providers with dedicated rare disease medicine services.

Today we have in excess of 200,000 patients, more than 1,500 employees and an annual turnover of c.£1.9billion.

Growing in size, service and scope
In 2008 we were awarded our first European contract with a rare disease pharmaceutical company, starting with the supply of one orphan drug. Today our portfolio has grown to cover rare and ultra rare disease including ambient and cold chain, and now spans 50 different products delivered to over 3,000 customer points across Europe. In the last year, we’ve partnered with 40 pharmaceutical companies and supplied 250,000 units of orphan medications for rare and ultra-rare diseases.

Your partner in Europe
Our role is to represent your pharmaceutical company in the best possible way to healthcare providers, patients and families. We’ll bring innovation and efficiency to you as your European partner.